Literature DB >> 20726552

Comparative proteomic analysis of triclabendazole response in the liver fluke Fasciola hepatica.

Gustavo Chemale1, Samirah Perally, E James LaCourse, Mark C Prescott, Laura M Jones, Deborah Ward, Myles Meaney, Elizabeth Hoey, Gerard P Brennan, Ian Fairweather, Alan Trudgett, Peter M Brophy.   

Abstract

Control of Fasciola hepatica infections of livestock in the absence of vaccines depends largely on the chemical triclabendazole (TCBZ) because it is effective against immature and adult parasites. Overdependence on a single drug and improper application is considered a significant factor in increasing global reports of fluke resistant to TCBZ. The mode(s) of action and biological target(s) of TCBZ are not confirmed, delaying detection and the monitoring of early TCBZ resistance. In this study, to further understand liver fluke response to TCBZ, the soluble proteomes of TCBZ-resistant and TCBZ-susceptible isolates of F. hepatica were compared with and without in vitro exposure to the metabolically active form of the parent drug triclabendazole sulphoxide (TCBZ-SO), via two-dimensional gel electrophoresis (2-DE). Gel image analysis revealed proteins displaying altered synthesis patterns and responses both between isolates and under TCBZ-SO exposure. These proteins were identified by mass spectrometry supported by a F. hepatica expressed sequence tag (EST) data set. The TCBZ responding proteins were grouped into three categories; structural proteins, energy metabolism proteins, and "stress" response proteins. This single proteomic investigation supported the reductionist experiments from many laboratories that collectively suggest TCBZ has a range of effects on liver fluke metabolism. Proteomics highlighted differences in the innate proteome profile of different fluke isolates that may influence future therapy and diagnostics design. Two of the TCBZ responding proteins, a glutathione transferase and a fatty acid binding protein, were cloned, produced as recombinants, and both found to bind TCBZ-SO at physiologically relevant concentrations, which may indicate a role in TCBZ metabolism and resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20726552     DOI: 10.1021/pr1000785

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  14 in total

1.  Molecular identification and characterization of leucine aminopeptidase 2, an excretory-secretory product of Clonorchis sinensis.

Authors:  Chuanhuan Deng; Jiufeng Sun; Xuerong Li; Lexun Wang; Xuchu Hu; Xiaoyun Wang; Wenjun Chen; Xiaoli Lv; Chi Liang; Wenfang Li; Yan Huang; Ran Li; Zhongdao Wu; Xinbing Yu; Jin Xu
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Fasciola hepatica and Schistosoma mansoni: identification of common proteins by comparative proteomic analysis.

Authors:  Nawal M Boukli; Bonnibel Delgado; Martha Ricaurte; Ana M Espino
Journal:  J Parasitol       Date:  2011-03-11       Impact factor: 1.276

3.  Transcriptomic and proteomic profiling of peptidase expression in Fasciola hepatica eggs developing at host's body temperature.

Authors:  Jana Ilgová; Jiří Vorel; Pavel Roudnický; Lucie Škorpíková; Martin Horn; Martin Kašný
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

4.  Effect of regulatory T cells on the efficacy of the fatty acid-binding protein vaccine against Schistosoma japonicum.

Authors:  Chun-Lian Tang; Rong-Hui Zhang; Zhi-Ming Liu; Huang Jin; Long He
Journal:  Parasitol Res       Date:  2019-01-04       Impact factor: 2.289

Review 5.  The omic approach to parasitic trematode research-a review of techniques and developments within the past 5 years.

Authors:  Orçun Haçarız; Gearóid P Sayers
Journal:  Parasitol Res       Date:  2016-04-28       Impact factor: 2.289

6.  Proteomic profiling and protein identification by MALDI-TOF mass spectrometry in unsequenced parasitic nematodes.

Authors:  Paul Millares; E James Lacourse; Samirah Perally; Deborah A Ward; Mark C Prescott; Jane E Hodgkinson; Peter M Brophy; Huw H Rees
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

7.  Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs.

Authors:  Santiago Radio; Santiago Fontenla; Victoria Solana; Anna C Matos Salim; Flávio Marcos Gomes Araújo; Pedro Ortiz; Cristian Hoban; Estefan Miranda; Valeria Gayo; Fabiano Sviatopolk-Mirsky Pais; Hugo Solana; Guilherme Oliveira; Pablo Smircich; José F Tort
Journal:  Parasit Vectors       Date:  2018-01-24       Impact factor: 3.876

8.  Recombinant Fasciola hepatica fatty acid binding protein suppresses toll-like receptor stimulation in response to multiple bacterial ligands.

Authors:  Marcos J Ramos-Benítez; Caleb Ruiz-Jiménez; Vasti Aguayo; Ana M Espino
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

9.  Comparative Proteomics Analysis of Anisakis simplex s.s.-Evaluation of the Response of Invasive Larvae to Ivermectin.

Authors:  Iwona Polak; Elżbieta Łopieńska-Biernat; Robert Stryiński; Jesús Mateos; Mónica Carrera
Journal:  Genes (Basel)       Date:  2020-06-26       Impact factor: 4.096

10.  Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems.

Authors:  Belén Vicente; Julio López-Abán; Jose Rojas-Caraballo; Esther del Olmo; Pedro Fernández-Soto; Antonio Muro
Journal:  Parasit Vectors       Date:  2016-04-18       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.